Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 18/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9510585 | 1.00 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL6478689 | 0.89 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL6478692 | 0.89 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL8061918 | 0.89 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL8061920 | 0.89 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL17570381 | 0.89 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL5629946 | 0.89 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL17873667 | 0.88 | OPRK1 (1.00) | OPRK1CYP2D6 | |
| SCHEMBL17873664 | 0.88 | OPRK1 (1.00) | OPRK1CYP2D6 | |
| SCHEMBL6979053 | 0.88 | OPRK1 (0.78) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960612-B2 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 2005-11-01 | — | — | US | claimed |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2004-11-04 | — | — | US | claimed |
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | KRUSE LAWRENCE I (US) | 2003-12-25 | — | — | US | claimed |
| US-20020042399-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-04-11 | — | — | US | claimed |
| US-6028063-A | ADMINISTERING COMPOUND WITH OPIOID ACTIVITY | ADOLOR CORPORATION (US) | 2000-02-22 | — | — | US | claimed |
| EP-0254545-B1 | DIAMINE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-06 | — | — | EP | claimed |
| EP-0254545-A2 | Diamine compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-01-27 | — | — | EP | claimed |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2021-09-07 | — | — | US | disclosed |
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2019-11-21 | — | — | US | disclosed |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-01-18 | — | — | US | disclosed |
| US-9815824-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2017-11-14 | — | — | US | disclosed |
| US-7294647-B2 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION (US) | 2007-11-13 | — | — | US | disclosed |
| US-6180623-B1 | USED AS ANALGESICS AND ANTI-PRURITIC AGENTS | ADOLOR CORPORATION | 2001-01-30 | — | — | US | disclosed |
| US-6057323-A | PIPERAZINE DERIVATIVES | ADOLOR CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-6054445-A | KAPPA OPIOID AGONIST ACTIVITY; ANALGESICS AND ANTI-PRURITIC AGENTS | ADOLOR CORPORATION (US) | 2000-04-25 | — | — | US | disclosed |
| US-6028063-A | ADMINISTERING COMPOUND WITH OPIOID ACTIVITY | ADOLOR CORPORATION (US) | 2000-02-22 | — | — | US | disclosed |
| US-5981513-A | ADMINISTERING ANTI-PRUITIC COMPOUNDS TO PATIENTS | ADOLOR CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0254545-B1 | DIAMINE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-06 | — | — | EP | disclosed |
| EP-0254545-A2 | Diamine compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 946/4885CYP3A4 798/4885 |
| US-20020042399-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 843/4885CYP3A4 695/4885 |
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 322/4885CYP3A4 392/4885 |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 886/4885CYP3A4 737/4885 |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 341/4885CYP3A4 410/4885 |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRL1 | OPRK1 1/4885CYP2D6 371/4885CYP3A4 493/4885 |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRL1 | OPRK1 1/4885CYP2D6 371/4885CYP3A4 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.